ARCA biopharma Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Tom Keuer
Chief Executive Officer (CEO)
US$400.8k
Compensación total
| Porcentaje del salario del CEO | 84.8% |
| Permanencia del CEO | 9.4yrs |
| Participación del CEO | 0.005% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 7.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth
Apr 04
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Sep 24ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play
May 03Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Mar 18Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Nov 27Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
Jul 15Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
Mar 30Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19
Dec 15We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth
Dec 15
ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment
Nov 24ARCA biopharma reports Q3 results
Nov 02Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$6m |
| Dec 31 2023 | US$401k | US$340k | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$5m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$449k | US$340k | -US$10m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$17m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$421k | US$339k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$19m |
| Jun 30 2021 | n/a | n/a | -US$16m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$631k | US$285k | -US$10m |
| Sep 30 2020 | n/a | n/a | -US$6m |
| Jun 30 2020 | n/a | n/a | -US$5m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$304k | US$283k | -US$5m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$327k | US$303k | -US$8m |
| Sep 30 2018 | n/a | n/a | -US$11m |
| Jun 30 2018 | n/a | n/a | -US$13m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | US$457k | US$302k | -US$18m |
Compensación vs. Mercado: La compensación total de Tom($USD400.80K) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Tom ha sido consistente con los resultados de la empresa en el último año.
CEO
Tom Keuer (64 yo)
9.4yrs
Permanencia
US$400,802
Compensación
Mr. Thomas A. Keuer, also known as Tom, serves as President & Principal Executive Officer of ARCA Biopharma, Inc. since April 3, 2024 and has been the Chief Operating Officer since December 1, 2014. Mr. Ke...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Independent Director | 17yrs | US$162.50k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$150.00k | 0% $ 0 | |
| Independent Chairman of the Board | 10.7yrs | US$195.00k | 0.34% $ 174.5k | |
| Director | 1.9yrs | US$130.00k | 0% $ 0 | |
| Independent Director | 1.4yrs | US$40.00k | 0% $ 0 |
7.3yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de ABIO se considera experimentada (7.2 años de antigüedad promedio).